KR102623473B1 - 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 - Google Patents

피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 Download PDF

Info

Publication number
KR102623473B1
KR102623473B1 KR1020207000292A KR20207000292A KR102623473B1 KR 102623473 B1 KR102623473 B1 KR 102623473B1 KR 1020207000292 A KR1020207000292 A KR 1020207000292A KR 20207000292 A KR20207000292 A KR 20207000292A KR 102623473 B1 KR102623473 B1 KR 102623473B1
Authority
KR
South Korea
Prior art keywords
mmol
phenyl
esi
nmr
solvent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207000292A
Other languages
English (en)
Korean (ko)
Other versions
KR20200014894A (ko
Inventor
니콜라스 알. 우츠
프라빈 수드하카르 시루데
앤드류 쿽 비엣
앤드류 ?o 비엣
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20200014894A publication Critical patent/KR20200014894A/ko
Application granted granted Critical
Publication of KR102623473B1 publication Critical patent/KR102623473B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/98—Nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207000292A 2017-06-09 2018-06-08 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 Active KR102623473B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517211P 2017-06-09 2017-06-09
US62/517,211 2017-06-09
PCT/US2018/036631 WO2018227065A1 (en) 2017-06-09 2018-06-08 Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists

Publications (2)

Publication Number Publication Date
KR20200014894A KR20200014894A (ko) 2020-02-11
KR102623473B1 true KR102623473B1 (ko) 2024-01-09

Family

ID=62779078

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207000292A Active KR102623473B1 (ko) 2017-06-09 2018-06-08 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제

Country Status (6)

Country Link
US (1) US11186544B2 (https=)
EP (1) EP3634412A1 (https=)
JP (1) JP7183193B2 (https=)
KR (1) KR102623473B1 (https=)
CN (1) CN110996950B (https=)
WO (1) WO2018227065A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6811241B2 (ja) 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
EP3634958B1 (en) 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
KR102803660B1 (ko) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
CN113166134B (zh) 2018-11-26 2024-06-14 百时美施贵宝公司 作为甲酰肽2受体激动剂的吡咯烷酮衍生物
EP3986903B1 (en) * 2019-06-18 2023-05-10 Bristol-Myers Squibb Company Biaryl dialkyl phosphine oxide fpr2 agonists
EP3789378A1 (en) * 2019-09-06 2021-03-10 Grünenthal GmbH Piperidines or piperidones substituted with urea and heteroaryl
CA3185263A1 (en) 2020-07-09 2022-01-13 James A. Johnson Pyrazolone formyl peptide 2 receptor agonists
KR20230051525A (ko) 2020-08-12 2023-04-18 브리스톨-마이어스 스큅 컴퍼니 옥소피롤리딘 우레아 fpr2 효능제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016189876A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6790845B2 (en) * 2001-04-09 2004-09-14 Bristol-Myers Squibb Pharma Company Fused heterocyclic inhibitors of factor Xa
WO2006063113A2 (en) * 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
ES2711363T3 (es) * 2012-04-16 2019-05-03 Allergan Inc Derivados de (2-ureidoacetamido)alquilo como moduladores del receptor 2 de péptidos formilados
NZ720508A (en) * 2013-11-28 2019-03-29 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
JP6746614B2 (ja) 2015-05-27 2020-08-26 杏林製薬株式会社 ウレア誘導体、またはその薬理学的に許容される塩
MX2018005756A (es) * 2015-11-24 2018-08-01 Squibb Bristol Myers Co Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
JP6811241B2 (ja) * 2015-12-10 2021-01-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ピペリジノンホルミルペプチド受容体２およびホルミルペプチド受容体１アゴニスト
ES2829550T3 (es) * 2016-07-07 2021-06-01 Bristol Myers Squibb Co Ureas cíclicas espiro-condensadas como inhibidores de ROCK
TW201815762A (zh) * 2016-09-21 2018-05-01 德商歌林達有限公司 經尿素及苯基取代之６員環狀胺或內醯胺
KR102615099B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 아릴 헤테로시클릭 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
EP3634958B1 (en) 2017-06-09 2021-07-21 Bristol-Myers Squibb Company Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists
KR102615095B1 (ko) 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
KR102803660B1 (ko) * 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 페닐피롤리디논 포르밀 펩티드 2 수용체 효능제
EP3986903B1 (en) * 2019-06-18 2023-05-10 Bristol-Myers Squibb Company Biaryl dialkyl phosphine oxide fpr2 agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016189876A1 (en) * 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof

Also Published As

Publication number Publication date
JP7183193B2 (ja) 2022-12-05
CN110996950B (zh) 2023-04-04
JP2020523327A (ja) 2020-08-06
EP3634412A1 (en) 2020-04-15
US20200123108A1 (en) 2020-04-23
WO2018227065A1 (en) 2018-12-13
CN110996950A (zh) 2020-04-10
US11186544B2 (en) 2021-11-30
KR20200014894A (ko) 2020-02-11

Similar Documents

Publication Publication Date Title
KR102623473B1 (ko) 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
US11708327B2 (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists
KR102772801B1 (ko) 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제
EP3986903B1 (en) Biaryl dialkyl phosphine oxide fpr2 agonists
HK40035056A (en) Phenylpyrrolidinone formyl peptide 2 receptor agonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200106

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210607

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230512

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20231005

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240105

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240105

End annual number: 3

Start annual number: 1

PG1601 Publication of registration